July 2020

Get to know the Taiwan Bio Industry Organization (TBIO)

I-Ming Chu
Professor of Chemical Engineering
National Tsing Hua University, Taiwan

Since its founding in 1989, the Taiwan Bio Industry Organization (TBIO) has been working closely with industry, government and academia to promote biotechnology. Currently, more than 100 organizations and 3,000 individuals join TBIO. Their background represents the entire life sciences industry spectrum, including biotechnology, pharmaceutical, diagnostics, medical devices and materials, agricultural biotechnology, and nutraceuticals sectors. Presently, Dr. Johnsee Lee holds the position of President of TBIO. Dr. Lee held many important positions in the past, like CEO of Development Center for Biotechnology (DCB) and President of ITRI, is a well-known pioneer and proponent for biotechnology in Taiwan.

General Mission
One of TBIO's key responsibilities is organizing the BioTaiwan Convention, an annual week-long festival of biotech-themed events held in Taipei. Through this gathering, TBIO helps facilitate networking, licensing and cooperation opportunities between investors, researchers, biotech companies and other key stakeholders, with the event also playing an important role in improving Taiwan's visibility within the global biotechnology community. The 2020 Convention, though affected by the coronavirus, will be held again July 22-26, 2020. The COVID-19 pandemic has necessitated a transformation of the event into a mix of online and live formats. Please come and attend as originally scheduled, please check the website BIO Asia–Taiwan 2020 Online + Live! for more information. On-line conferences will be available, the topics include Combating the Pandemic, Advanced Therapies, Precision Medicine, Digital Health and Investment & Collaboration.

Promoting communication between government and industry
In addition, TBIO organizes regular conferences, seminars and meetings inviting key industry leaders and government representatives to address members' interests and concerns. In this way, TBIO acts as a bridge connecting the private sector, academia, government, and international interests.

Cultivating biotechnology industry talent
In 2015 TBIO helped establish the Bio Industry Academy (BIA), a training organization with a mission to better prepare local talent for employment in Taiwan's booming biopharmaceutical industry, and to upgrade the industry as a whole. Training topics offered by BIA to date include new drug development, manufacturing processes, industry-related business, finance and management, among others.

Encouraging outstanding performance and innovation
TBIO organizes the annual Taiwan Bio-Industry Organization Awards, in Outstanding Company of the Year, Emerging Company of the Year, and Innovation of the Year categories. In doing so, TBIO aims to recognize local achievements and encourage innovation within this important industry, helping facilitate its further growth and the development of the entire biotechnology ecosystem.

Contact Information
Taiwan Bio Industry Organization
TEL: 886-2-77003883 Mobile: 886-908-982-913
FAX: 886-2-7700-3884 E-Mail:
Address:Bldg. E, No.107, Ln. 130, Sec. 1, Academia Rd., Nangang, Taipei, Taiwan 115

TBIO 이미지 TBIO President Dr. Johnsee Lee signed MOU with AFOB President Prof.
Wen-Chien Lee at the 2019 ACB

Excerpt from CEO& Interview

To celebrate its 10th anniversary of EuBiologics Co., Ltd, CEO&, a Korean business magazine, had a chance to talk with CEO Yeong Ok Baik of EuBiologics. “As a COVID-19 pandemic continues to prolongation, development of preventive vaccines gets global attention” Said Baik. “Recently, wehave signed a consortium business agreement with several Korean biopharmaceutical companies and institution to develop COVID-19 preventive vaccine, and now we are spurring our research and development process”. With the COVID-19 vaccine development status, CEO Baik have talked about the vision and the plan of EuBiologics preparing for the next 10 years.

EuBiologics currently working on development pipeline using their own platform technology EuIMT (Immune Modulation Technology, using EcML that enhances immune system) and EuVCT (Virus Conjugated Technology, using recombinant protein rCRM197). Clinical studies for TCV (Typhoid Conjugated Vaccine), PCV (Pneumococcal Conjugated Vaccine) and MCV (Meningococcal Conjugated Vaccine), which were developed using EuVCT, are currently working in progress both in domestically and globally.

Meanwhile in the last board meeting, they have decided to invest and establish Joint Venture with American biopharmaceutical company called Pop Biotech.The ultimate goal of the joint venture is to develop premium vaccines and advance into the global market by combining EuBiologics’ immuno-adjuvant technology along with Pop Biotech’ SNAP (antigen delivery)technology.

Euniologics 이미지 EuBiologics’ Second Plant (V Plant) in Chuncheon, Korea


CBC 이미지